Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

ClinicalTrials.gov ID: NCT06137742

Public ClinicalTrials.gov record NCT06137742. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1 / 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ESCALATING DOSES OF PF-07868489 IN HEALTHY ADULT PARTICIPANTS AND, ADDITIONALLY, CLINICAL ACTIVITY OF REPEAT DOSES IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants. Part B: A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.

Study identification

NCT ID
NCT06137742
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
97 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 16, 2023
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update posted
Aug 20, 2026

2023 – 2026

United States locations

U.S. sites
16
U.S. states
4
U.S. cities
8
Facility City State ZIP Site status
Anaheim Clinical Trials, LLC Anaheim California 92801
UCI Health - Costa Mesa Costa Mesa California 92627
UCI Health Center for Innovative Health Therapies (CIHT) Orange California 92868
University of California, Irvine Medical Center Orange California 92868
UCSF Health St. Mary's Hospital San Francisco California 94117
UCSF Helen Diller Medical Center at Parnassus Heights San Francisco California 94143
Icahn school of medicine at Mount Sinai New York New York 10029
Mount Sinai Hospital New York New York 10029
Eastowne 100 Medical Office Building Chapel Hill North Carolina 27514
Eastowne Medical Office Building - Clinical Research Unit Chapel Hill North Carolina 27514
UNC Health - Eastowne Medical Office Chapel Hill North Carolina 27514
UNC Hospitals Chapel Hill North Carolina 27514
Investigational Drug Services Pharmacy Morrisville North Carolina 27560
Medical University of South Carolina - Nexus Charleston South Carolina 29425
Medical University of South Carolina - Radiology Charleston South Carolina 29425
Medical University of South Carolina Charleston South Carolina 29425

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06137742, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06137742 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →